Massive Chinese Stealth Flying Wing Emerges At Secretive Base
The image of the previously unseen aircraft sitting outside of an already intriguing hangar complex at an airfield notorious for advanced air combat programs comes to us from the Planet Labs archive. The image was taken on May 14th, 2025, and just appeared in the database.
The image shows China's secretive test base near Malan in Xinjiang province, which is known to be on the leading edge of the country's unmanned aircraft development efforts. Specifically, the craft was parked outside of a sprawling new facility that was built very recently to the east of the base, connected to it by a very long taxiway leading to a security gate.
Construction of the installation began just over two years ago. The high-security site is very densely populated with hangars of various sizes. These include estimated (based on early construction satellite images) 70-meter, 50-meter, 20-meter, and 15-meter bays. The craft in question is sitting outside one of the largest bays. The low-slung large hangars are reminiscent of the shelters for U.S. B-2 bombers at Whiteman Air Force Base in Missouri or infrastructure we see at the U.S. Air Force's Plant 42 in Palmdale, California, associated with flying-wing aircraft. The smaller bays at Malan are a bit more of a puzzle.
It wasn't previously apparent what this facility was intended to do, but now it seems clearer that it may be a testing base for China's next generation air combat ecosystem, which would include aircraft of multiple sizes — from the H-20, to large stealthy flying wing drones, the the tri-engined J-36, to the J-XDS fighter, and of course, smaller tactical drones. The U.S. Air Force is developing its Next Generation Air Dominance (NGAD) and Long-Range Strike (LRS) family of systems in a similar manner. This would perfectly explain the puzzling variety of bay sizes for such a compact base and its high-security nature. Still, this is just a guess based on the very small amount of visual evidence available.
The newly emerged aircraft itself appears impressive. It is a large flying wing that has a wingspan of roughly 52 meters, or about 170 feet. The B-2 Spirit is 172 feet wide, for comparison, and the B-21 is going to be a bit smaller. Maybe the best explanation is that this is a very large, high-altitude, long-endurance (HALE) stealthy drone — similar to the supposed U.S. RQ-180 — but this would be the biggest we have ever seen. China is developing a number of flying-wing type designs of various sizes, including large HALE drones, but nothing at this scale, at least that we know about. It is also worth mentioning that the aircraft seen in the new imagery has a close resemblance to one that was spotted passing over the Philippines in 2021.
Alternatively, its size would fit more logically into the profile of the H-20 — China's first and so far unseen stealth bomber. As such, this could be our first look at that aircraft, ever.
The planform is similar to that of the B-21, with the wingtips appearing to be clipped at an angle, similar to it and the B-2. While there is a white area that appears to give the left wing a sharper tip, that is not the case as proven by the shadows below it. The sweep looks less than a B-2 or B-21, pointing to endurance at altitude as a significant design driver. There also appears to be a center barrel or domed section. This is customary on flying-wing designs. It can house the cockpit and additional internal volume for a manned aircraft or even the intake and the engines for an unmanned ones.
No cockpit is visible, nor features like inlets, but the resolution really limits making out those kinds of details.
Finally, and most interestingly, there appears to be a small set of angled vertical tails, at least as indicated by the shadows and what seem like vertical extensions on its upper management. This is not a conclusive feature. It could be something else causing this optical property, but it's worth noting that small vertical tails on large flying wing concepts are not unheard of. It is very challenging to impart stability of this kind of large flying-wing design, and small tails would greatly assist in this. You can read all about this here.
What is critical to state here is that the emergence of this aircraft is very unlikely to be an accident. China is fully aware that commercial satellites are passing over at any given time, and they could keep hidden any program they wanted. Mistakes could happen, but, taken at face value, it's far more likely China was ready for this aircraft to be seen by satellites. It's also possible that they could use exactly this knowledge for information warfare purposes, rolling out a mockup or decoy in order to confuse foreign intelligence units, which are watching this facility far more closely and with much better resolution than what a publicly accessible commercial satellite service can provide. These factors are always worth remembering. Still, the fact is that this facility also looks built for such a machine, at least in part.
So there you have it. This could be our first look at China's stealth bomber or a very long-reaching HALE drone — either of which could be highly problematic when it comes to enabling targeting of American ships and installation deep in the Pacific, for instance. This is the third major revelation we have had just in the last seven months when it comes to China's rapidly evolving next-generation air combat capabilities, and it probably won't be the last for 2025.
Author's note: Edited to include wing sweep features.
Contact the author: Tyler@twz.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Pharma interest can plug NIH funding gap: Illumina CEO
Genetic sequencing company Illumina (ILMN) has had a rough few years. It has battled activist investors, faced off with the Federal Trade Commission, and, most recently, agreed to a $9.8 million settlement with the Department of Justice over a cybersecurity breach. To add to the pile: sanctions in China and the Trump administration cutting National Institutes of Health (NIH) funding, which the company relies heavily on for clinical research. The numbers don't lie. The stock is down more than 21% in the past year and sank more than 11% in after-hours trading Thursday after the company reported an earnings miss for the second quarter. The company reported $1.06 billion in revenues compared to expected revenues of $1.05 billion. Adjusted earnings per share came in at $1.19 compared to estimates of $1.01. But CEO Jacob Thaysen told Yahoo Finance he remains positive about the company's near-term growth. Why? Because, in part, pharmaceutical companies can provide a new market. "Now, we're shifting from small things to really big programs. Some of the things making up for the reduction from the NIH is kind of indirect, but pharma is getting more interest in these big programs," he said, noting that 15% of the company is exposed to government research funding. "It's not only about sequencing itself, but really using massive amounts of data ... to really identify new drug targets and understand a disease," Thaysen said. The idea to use patient data to help the pharmaceutical world was also identified by 23andMe, which recently came out of bankruptcy through a nonprofit led by founder Anne Wojcicki. Thaysen said that unlike 23andMe, which he has worked with, his company is not going to pursue drug development on its own. "We have a lot of pharma companies that are very excited to work with us," he said. In addition to genetic testing of patient samples, the company is looking at growing in the preventative side of care with cancer screenings. The oncology business, Thaysen said, will have healthy growth over the next 10 or so years. China China banned importations of the San Diego-based company's sequencing machines earlier this year as part of its retaliatory actions to Trump's tariff war. Thaysen said he is working with regulators to try to reverse that, but "in the meantime, that business is declining, and we are expecting it to be flat." In fact, though China has historically been about 10% of the company's business, it contributed to half of the decline in earnings this past week. "China was never a huge part of Illumina's business. When it was the largest, it was just around 10%. We're down to 5% of the business," Thaysen told Yahoo Finance. But because of the tariff war and China's goals to boost its domestic innovation market, Illumina has faced a setback in its market power there from local competition. "As soon as there is a Chinese alternative that is good enough, then you will see that the Chinese government is pushing for the Chinese population, the Chinese companies to use that technology," Thaysen said. He added that even with the increased competition, China is an appealing market to remain in. Analysts are still waiting to see more progress on Illumina's return to growth. Jefferies analyst Tycho Peterson said in a note to clients that the firm will reiterate its Hold rating until things settle: "While the clinical traction is encouraging, we view clarity on near-term headwinds (A&G, China, Roche) and a path to sustainable HSD growth as key to a more constructive view. Reiterate Hold." Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Lufax Holding Ltd (LU) Sells $64M in Bad Loans to Cut Credit Risk, Stabilize Outlook
We recently compiled a list of the 10 Best Low Cost Stocks To Buy Under $50. Lufax Holding Ltd stands fourth on our list. Lufax Holding Ltd (NYSE:LU), a leading Chinese fintech firm serving small and micro businesses, is undergoing strategic shifts to navigate a challenging market in 2025. A key recent development was the sale of non-performing loans (NPLs) through its subsidiary, Ping An Consumer Finance. The transaction involved offloading 469 million yuan in NPLs for 36.44 million yuan to Sh China Merch Ping An Asset Management. This move reduced credit risk and supported a drop in the company's loan portfolio by 18%, helping stabilize investor sentiment amid asset quality concerns. In addition to asset optimization, Lufax Holding Ltd (NYSE:LU) is focusing on digital transformation through new partnerships and AI-driven innovation. These efforts aim to boost operational efficiency and profitability while enhancing its competitive edge in a crowded fintech market. The business is also pursuing cost-cutting measures as part of a broader strategy to improve earnings. Despite these positive steps, cheap stocks to buy like Lufax Holding Ltd (NYSE:LU) saw sharp declines in late July, dropping over 11% and 12% on back-to-back days. The sell-off reflected investor concerns over limited near-term catalysts and persistent pressure from traditional banks. An individual using a laptop to access the fintech platform to manage their finances. Looking ahead, the corporation plans to continue managing credit risk proactively, expand its digital offerings, and pursue strategic partnerships. These efforts are expected to support earnings growth and may enable the resumption of dividends by the end of the 2025 fiscal year. While we acknowledge the potential of LU as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.

Wall Street Journal
3 hours ago
- Wall Street Journal
Trump's AI Strategy Against China Gets Its First Big Test
The U.S. and China just released competing plans to win the artificial-intelligence race. They will get their first test this coming week when the superpowers pitch Asian countries that are picking sides. The Trump administration is expected to tout its strategy for exporting American AI for a 21-nation Asia-Pacific Economic Cooperation meeting in South Korea focused on technology, which begins Monday, U.S. officials said. The goal is to explain why U.S. chips and software are best for deploying AI in sectors such as healthcare and make inroads against China.